Table 4.
Control Group, Randomization, and Masking of Recent Myopia Control Trials
| Author, Year | Intervention | Control | Rando-mization | Strati-fication | Masking | Initial Study Length, y | Rebound Assessment |
|---|---|---|---|---|---|---|---|
| Kanda et al., 2018144 | Spectacle (novel plus design) | Spectacle (SV) | Y | N | Y | 2 | N |
| Lam et al., 2020132 | Spectacle (novel plus design) | Spectacle (SV) | Y | N | Y | 2 | N |
| Li et al., 2019146 | OK | Spectacle (SV) | N | N | N | 1 | Y (1 month) |
| Ruiz-Pomeda et al., 2018145 | SCL (concentric bifocal) | Spectacle(SV) | Y | Y | N | 2 | N |
| Chamberlain et al., 2019134 | SCL (concentric bifocal) | SCL (SV) | Y | Y | Y | 3* | Y (planned)† |
| Sankaridurg et al., 2019135 | SCL (multifocal and novel design) | SCL (SV) | Y | N | Y | 2 | N |
| Walline et al., 2020136 | SCL (multifocal +1.50 and +2.50 add) | SCL (SV) | Y | Y | Y | 3* | Y (planned)† |
| Azuara-Blanco et al., 2019147b | Atropine (0.01%) | Placebo | Y | N | Y | 2 | N |
| Joachimsen et al., 2019147 | Atropine (0.01%) | None | N | N | N | 1 | N |
| McCrann et al., 2019148 | Atropine (0.01%) | Placebo | Y | Y | Y | 3 | Y (study year 3) |
| Yam et al., 2019149 | Atropine (0.01%, 0.025%, 0.05%) | Placebo (year 1 only) | Y | Y | Y | 3 | Y (study year 3) |
| Huang et al., 2019150 | SCL (multifocal) plus atropine (0.01%) | Historical (SCL SV and SCL multifocal) | N | N | N | 3 | N |
| Tan et al., 2019151 | OK plus atropine (0.01%) | OK only | Y | N | Y | 2 | N |
SV, single vision.
*Followed for an additional period after ending randomization.
† Based on communication with authors.